NCT07479433

Brief Summary

The objective of Heartflow's NAVIGATE-PCI Registry is to collect observational data about the management of patients before and after deployment of Heartflow's PCI Navigator.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
81mo left

Started Mar 2026

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Mar 2026Dec 2032

First Submitted

Initial submission to the registry

March 11, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

March 11, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 18, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2026

Expected
6.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2032

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

7 months

First QC Date

March 11, 2026

Last Update Submit

March 18, 2026

Conditions

Keywords

CADPCI NavigatorCT-Guided PCIPCI

Outcome Measures

Primary Outcomes (1)

  • Primary Endpoint

    The primary endpoint will be assessed only in Group 2 and is a change in procedural plan following review of the information provided by PCI Navigator compared to procedural plan with angiographic imaging alone. The primary endpoint will be measured by calculating the percentage of patients in whom a change of plan was documented following review of the PCI Navigator tool compared to the plan documented prior to using the tool.

    90 Days

Secondary Outcomes (6)

  • Changes in confidence with and without PCI Navigator (assessed in Groups 2 and 3 as two separate analyses)

    90 days for Group 2, 18 months for Group 3

  • Change in procedural time with and without PCI Navigator

    90 days

  • Change in contrast usage with and without PCI Navigator

    90 days

  • Change in radiation usage during PCI with and without PCI Navigator

    90 days

  • Change in invasive imaging (angiographic or other) with and without PCI Navigator

    90 days

  • +1 more secondary outcomes

Other Outcomes (2)

  • Exploratory and Safety Endpoint

    5 years

  • Exploratory and Safety Endpoint

    5 years

Study Arms (3)

Group 1: No PCI Navigator

This group includes consecutive patients who have undergone a CCTA a maximum of 90 days prior to an elective PCI at the study site; the CCTA is not required to have been used in procedural planning but must have acceptable image quality according to Heartflow's image quality requirements

Group 2: Intraprocedural PCI Planning

This group includes patients who had a CCTA and a referral for elective PCI following the introduction of the PCI Navigator at the study site. The PCI should be performed no more than 90 days following the CCTA. Interventionalists will document their procedural plan after initial invasive angiographic images are reviewed but before reviewing the information provided by the PCI Navigator, and then again after reviewing the information provided by the PCI Navigator. Usage of invasive imaging following review of the PCI Navigator is at the discretion of the interventionalist.

Diagnostic Test: Heartflow PCI Navigator

Group 3: Preprocedural Planning

This group includes patients who had a CCTA and a referral for elective PCI following the introduction of the PCI Navigator at the study site. The PCI should be performed no more than 90 days following the CCTA. Interventionalists will document their procedural plan before reviewing the information provided by the PCI Navigator and prior to initial invasive angiographic imaging, and then again after reviewing the information provided by the PCI Navigator. Usage of angiographic and other invasive imaging following review of the PCI Navigator is at the discretion of the interventionalist.

Diagnostic Test: Heartflow PCI Navigator

Interventions

Heartflow PCI Navigator is the only integrated, AI-driven PCI planning tool that gives interventional cardiologists a patient-specific 3D model, detailing anatomy, plaque composition, and lesion-specific physiology, all aligned to optimize potential stent placement. PCI Navigator delivers a streamlined view of essential information for cath lab decision-making by integrating all relevant measurements, including IVUS-like and FFR-like pullback visualizations, into one seamless experience, which typically requires significant time and effort to obtain in the cath lab.

Group 2: Intraprocedural PCI PlanningGroup 3: Preprocedural Planning

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Deidentified data will be collected for all patients included in the registry who had a CCTA with acceptable image quality prior to elective PCI and are included by the site in the registry. Patients with prior CABG or patients with intervention planned in a previously stented vessel territory are excluded.

You may qualify if:

  • CCTA completed ≤90 days prior to elective PCI with acceptable image quality according to Heartflow's image quality requirements
  • Referred for elective PCI
  • Clinically stable without symptoms suggestive of acute coronary syndrome (ACS) at the time of the intervention

You may not qualify if:

  • ED presentation (at the time of the referral for PCI)
  • Previous coronary artery bypass graft (CABG)
  • Planned intervention in a previously stented vessel territory
  • Acute chest pain (in patients who have not been ruled out for ACS)
  • Participating in a conflicting study being undertaken during the PCI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wellstar Health System

Marietta, Georgia, 30060, United States

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Ziad Ali, MD, DPhil

    St. Francis Hospital & Heart Center Columbia University

    PRINCIPAL INVESTIGATOR
  • Todd C. Villines, MD

    University of Virginia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
5 Years
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 11, 2026

First Posted

March 18, 2026

Study Start

March 11, 2026

Primary Completion (Estimated)

September 30, 2026

Study Completion (Estimated)

December 31, 2032

Last Updated

March 23, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations